337.20
Madrigal Pharmaceuticals Inc stock is traded at $337.20, with a volume of 367.12K.
It is down -4.13% in the last 24 hours and up +23.01% over the past month.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
See More
Previous Close:
$351.71
Open:
$353.98
24h Volume:
367.12K
Relative Volume:
0.97
Market Cap:
$7.35B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-13.42
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
+1.35%
1M Performance:
+23.01%
6M Performance:
+38.61%
1Y Performance:
+54.69%
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MDGL
Madrigal Pharmaceuticals Inc
|
337.20 | 7.35B | 0 | -518.67M | -438.32M | -25.12 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.00 | 117.92B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
673.60 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
639.41 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
256.45 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
119.83 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
Jun-11-24 | Initiated | Wolfe Research | Outperform |
Apr-22-24 | Initiated | BofA Securities | Underperform |
Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
Mar-06-24 | Initiated | Citigroup | Buy |
Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
Dec-20-22 | Reiterated | Oppenheimer | Outperform |
Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
Dec-19-22 | Reiterated | Piper Sandler | Overweight |
Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
Oct-07-21 | Initiated | Jefferies | Buy |
Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
May-20-21 | Resumed | Goldman | Buy |
Nov-24-20 | Resumed | Evercore ISI | Outperform |
Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
Jul-31-20 | Initiated | Piper Sandler | Overweight |
Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
May-05-20 | Initiated | Chardan Capital Markets | Buy |
Jan-30-20 | Initiated | Canaccord Genuity | Buy |
Jan-09-20 | Upgrade | UBS | Neutral → Buy |
Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
Jun-25-19 | Initiated | Stifel | Hold |
Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
Feb-22-19 | Initiated | SVB Leerink | Outperform |
Jan-23-19 | Initiated | UBS | Neutral |
Dec-14-18 | Initiated | Wolfe Research | Outperform |
Dec-12-18 | Initiated | B. Riley FBR | Neutral |
Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
Sep-04-18 | Initiated | Citigroup | Buy |
Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Fiera Capital Corp Sells 4,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals to Announce Q4 and Full-Year 2024 Results with Live Webcast - MSN
Newbridge Financial Services Group Inc. Takes $1.30 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 - The Manila Times
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on - EIN News
Research Analysts Set Expectations for MDGL FY2024 Earnings - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
(MDGL) Long Term Investment Analysis - Stock Traders Daily
Rheos Capital Works Inc. Cuts Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
This Stock Just Doubled in 1 Day -- Is It Still a Buy? - The Motley Fool
Madrigal Pharmaceuticals CEO sells shares worth $531,020 - MSN
(01/29/25) Top Picks 2025: Madrigal Pharmaceuticals (MDGL) - Moneyshow.com
Madrigal Pharmaceuticals CEO sells shares worth $531,020 By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals executive sells shares worth $34,529 - MSN
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Insider Carole Huntsman Sells 347 Shares - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO Sells 1,584 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells 648 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Sells 103 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals executive sells shares worth $34,529 By Investing.com - Investing.com Canada
(MDGL) Trading Advice - Stock Traders Daily
Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis - MarketBeat
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
Brokers Issue Forecasts for MDGL FY2025 Earnings - MarketBeat
Cantor Fitzgerald Estimates MDGL FY2025 Earnings - Defense World
MDGL (Madrigal Pharmaceuticals) Long-Term Debt & Capital Le - GuruFocus.com
Cantor Fitzgerald Predicts MDGL FY2025 Earnings - MarketBeat
MDGL (Madrigal Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals’ Treatment Could Be a Blockbuster in the Making - TipRanks
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales - MSN
MDGL (Madrigal Pharmaceuticals) Change In Working Capital : $7.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals exec sells $461,789 in stock - MSN
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
MDGL (Madrigal Pharmaceuticals) Quick Ratio : 5.93 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH - Seeking Alpha
Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - Simply Wall St
MDGL (Madrigal Pharmaceuticals) Net Income From Continuing Operations : $-518.67 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) EV-to-EBITDA : -10.99 (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Capex-to-Operating-Cash-Flo - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Earnings Yield % : N/A% (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) 3-Year Book Growth Rate : 9.60% (As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Debt-to-Asset : 0.11 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals executive sells shares worth $120,847 - MSN
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):